Statement: Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial.
Primary_evidence: Inclusion Criteria:   HER-2 overexpressing breast cancer   Clinical stage 2-3B   Normal ejection fraction Exclusion Criteria:   Metastatic disease   Low ejection fraction